The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Clinical Use of Fluorodeoxyglucose F 18 Positron Emission Tomography for Detection of Renal Cell Carcinoma
Abstract
Purpose We evaluate the role of fluorodeoxyglucose F 18 positron emission tomography (PET) in patients with renal cell carcinoma (RCC) by retrospective review. To our knowledge this series is the largest reviewing the use of PET in patients with RCC. Materials and methods A total of 66 patients who underwent 90 PET scans for suspected or known RCC were identified. Dictated reports of PET, chest computerized tomography (CT), abdominal/pelvic CT and bone scan were examined with confirmation of results by histopathology or followup of at least 1 year. The accuracies of PET and conventional imaging modalities were compared. Results PET exhibited a sensitivity of 60% and specificity of 100% for primary RCC tumors (abdominal CT demonstrated 91.7% sensitivity and 100% specificity). For retroperitoneal lymph node metastases and/or renal bed recurrence, PET was 75.0% sensitive and 100.0% specific (92.6% sensitivity and 98.1% specificity for abdominal CT). PET had a sensitivity of 75.0% and a specificity of 97.1% for metastases to the lung parenchyma compared to 91.1% and 73.1%, respectively, for chest CT. PET had a sensitivity of 77.3% and specificity of 100.0% for bone metastases, compared to 93.8% and 87.2% for combined CT and bone scan. In 39 scans (32 patients) PET failed to detect RCC lesions identified by conventional imaging. Conclusions The role of fluorodeoxyglucose F 18 PET in the detection of RCC is limited by low sensitivity. With superior specificity PET may have a comple…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“or benign lesions and well-differentiated malignant lesions with low [18F]FDG avidity [122,123,124,125].”
From Influences on PET Quantification and Interpretation (2022) · cites this paper as [123]
Citations
Cites
Sivia, D. S. (1996) · Cited by 2,669
Schiepers, C. W., PENNINCKX, F. M., Vadder, N. D., Merckx, E., Mortelmans, L., Bormans, G. M., Marchal, G., Filez, L., & Aerts, R. (1995) · European Journal of Surgical Oncology · doi:10.1016/s0748-7983(95)97046-0 · Cited by 233
Avril, N. E., Dose, J., Jänicke, F., Ziegler, S. I., Römer, W., Weber, W., Herz, M., NATHRATH, W. B. J., Graeff, H., & Schwaiger, M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.17.1204 · Cited by 213
Ramdave, S., Thomas, G., Berlangieri, S. U., Bolton, D. M., Davis, I. D., DANGUY, H.-T., MacGregor, D. P., & Scott, A. M. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)65845-4 · Cited by 206
Bailet, J. W., Abemayor, E., Jabour, B. A., Hawkins, R. A., Ho, C., & Ward, P. H. (1992) · The Laryngoscope · doi:10.1288/00005537-199203000-00010 · Cited by 204
Scott, W. J., Schwabe, J. L., Gupta, N. C., Dewan, N. A., Reeb, S. D., & Sugimoto, J. T. (1994) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(94)90730-7 · Cited by 172
Safaei, A., Figlin, R. A., Hoh, C. K., Silverman, D. H. S., Seltzer, M., Phelps, M. E., & Czernin, J. (2002) · Clinical Nephrology · doi:10.5414/cnp57056 · Cited by 131
Miyakita, H., TOKUNAGA, M., Onda, H., USUI, Y., Kinoshita, H., Kawamura, N., & Yasuda, S. (2002) · International Journal of Urology · doi:10.1046/j.1442-2042.2002.00416.x · Cited by 115
Wu, H., Yen, R., Shen, Y., Kao, C., Lin, C., & Lee, C. (2002) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-002-0370-1 · Cited by 110
[Positron emission tomography in diagnosis of renal cell carcinoma].
Bachor, R., Kotzerke, J., Hw, G., Brandle, E., Sn, R., & Hautmann, R. E. (1996) · PubMed · Cited by 86
Cited by
Positron emission tomography for prostate, bladder, and renal cancer
Schöder, H., & Larson, S. M. (2004) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2004.06.004 · Cited by 337
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view
Boswell, C. A., & Brechbiel, M. W. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.04.001 · Cited by 247
Long, N. M., & Smith, C. S. (2011) · Insights into Imaging · doi:10.1007/s13244-010-0062-3 · Cited by 205
Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma
Wang, H., Ding, H., Chen, J.-H., Chao, C.-H., Lu, Y.-Y., Lin, W., & Kao, C. (2012) · Cancer Imaging · doi:10.1102/1470-7330.2012.0042 · Cited by 168
Antibodies for Molecular Imaging of Cancer
Wu, A. M., & Olafsen, T. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e31817b07ae · Cited by 150
Metadata
- Authors
- KANG, D. E., WHITE, R. L., ZUGER, J. H., SASSER, H. C., & TEIGLAND, C. M.
- Affiliations
- Carolinas Medical Center (US)
- ORCID
- WHITE, RICHARD L.
- Venue
- Journal of Urology
- Published
- 2004-05
- Volume
- 171
- Issue
- 5
- Pages
- 1806-1809
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2103792773
- Cited by
- 305
- References
- 14
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 4 · 2023: 7 · 2022: 14 · 2021: 6 · 2020: 6 · 2019: 16 · 2018: 14 · 2017: 13 · 2016: 19 · 2015: 17 · 2014: 15 · 2013: 16 · 2012: 20
- FWCI
- 14.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Journal of Urology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Keywords
- renal cell carcinoma, tumor detection, diagnostic accuracy, sensitivity and specificity, retroperitoneal lymph node metastasis, lung metastasis, bone metastasis, abdominal CT, chest CT, bone scintigraphy
- MeSH terms
- Adult, Aged, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Retrospective Studies, Tomography, Emission-Computed, Radiopharmaceuticals, Fluorodeoxyglucose F18
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Use of Fluorodeoxyglucose F 18 Positron Emission Tomography for Detection of Renal Cell Carcinoma. https://app.cochat.ai/papers/10.1097/01.ju.0000120241.50061.e4
- The paper
- KANG, D. E., WHITE, R. L., ZUGER, J. H., SASSER, H. C., & TEIGLAND, C. M. (2004). Clinical Use of Fluorodeoxyglucose F 18 Positron Emission Tomography for Detection of Renal Cell Carcinoma. Journal of Urology. https://doi.org/10.1097/01.ju.0000120241.50061.e4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
